Vanguard Group Inc Pyxis Oncology, Inc. Transaction History

Vanguard Group Inc

  • $5.12 Trillion
  • Q2 2024

A detailed history of Vanguard Group Inc transactions in Pyxis Oncology, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 2,060,444 shares of PYXS stock, worth $7.56 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,060,444
Previous 1,401,425 47.02%
Holding current value
$7.56 Million
Previous $5.97 Million 14.24%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024
BUY
$3.06 - $5.58 $2.02 Million - $3.68 Million
659,019 Added 47.02%
2,060,444 $6.82 Million
Q1 2024

May 10, 2024
BUY
$2.03 - $6.59 $192,322 - $624,336
94,740 Added 7.25%
1,401,425 $5.97 Million
Q4 2023

Feb 14, 2024
BUY
$1.4 - $2.09 $233,018 - $347,863
166,442 Added 14.6%
1,306,685 $2.35 Million
Q3 2023

Nov 14, 2023
BUY
$1.6 - $2.78 $70,070 - $121,747
43,794 Added 3.99%
1,140,243 $2.27 Million
Q2 2023

Aug 14, 2023
BUY
$2.46 - $4.07 $83,394 - $137,973
33,900 Added 3.19%
1,096,449 $2.81 Million
Q1 2023

May 15, 2023
BUY
$1.38 - $6.0 $199,716 - $868,332
144,722 Added 15.77%
1,062,549 $4.26 Million
Q4 2022

Feb 10, 2023
BUY
$1.14 - $2.0 $505 - $886
443 Added 0.05%
917,827 $1.23 Million
Q3 2022

Nov 14, 2022
BUY
$1.88 - $3.03 $128,411 - $206,961
68,304 Added 8.04%
917,384 $1.81 Million
Q2 2022

Aug 12, 2022
BUY
$2.02 - $4.53 $651,997 - $1.46 Million
322,771 Added 61.33%
849,080 $2.02 Million
Q1 2022

May 13, 2022
BUY
$4.04 - $11.43 $24,284 - $68,705
6,011 Added 1.16%
526,309 $2.13 Million
Q4 2021

Feb 14, 2022
BUY
$8.39 - $13.64 $4.37 Million - $7.1 Million
520,298 New
520,298 $5.71 Million

Others Institutions Holding PYXS

# of Institutions
86
Shares Held
28.5M
Call Options Held
134K
Put Options Held
5K
View Full List

About Pyxis Oncology, Inc.

PYXS Quotes by TradingView
  • Ticker PYXS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,096,400
  • Market Cap $129M
  • Description
  • Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, no...
More about PYXS
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email